Advanced Life Sciences Announces Appointment
of Leading Research Scientist to Board of Directors
Woodridge, Ill, May 23, 2001 - Advanced Life Sciences, Inc. announced
today the appointment of Israel (Rudi) Rubinstein, M.D. to its
Board of Directors. Dr. Rubinstein is a leading research scientist
in respiratory medicine at the Cancer Center, University of Illinois
at Chicago and in oncology at the VA Chicago Health Care System,
West Side Division.
"We are fortunate that a researcher of Dr. Rubinstein's
caliber has joined Advanced Life Sciences Board of Directors,"
said Dr. Sharon W. Ayd, Chief Operating Officer of Advanced Life
Sciences. "Rudi Rubinstein is an expert in the fields of
oncology and infection research. This, in addition to his strong
knowledge of drug development will help us in our choice and development
of therapeutic agents in those areas."
Dr. Rubinstein received an M.D. from Hebrew University-Hadassah
School of Medicine and completed fellowships in Respiratory Research
at the University of Toronto and in Cardiovascular Research at
the University of California San Francisco. Dr. Rubinstein is
Professor of Medicine and Professor of Pharmaceutics and Pharmacodynamics
at the Colleges of Medicine and Pharmacy, respectively, at the
University of Illinois at Chicago. He serves on the Editorial
Boards of numerous medical journals, is a consultant to the NIH
and has received several academic honors and awards. He has published
over 140 articles, contributed to six book chapters and holds
ten US patents. Dr. Rubinstein is also President and CEO of Hyperpeptide,
Inc., a start-up biopharmaceutical company.
Advanced Life Sciences, Inc., based in Woodridge, Illinois (http://www.advancedlifesciences.com)
is a privately held, early-stage pharmaceutical technology development
company that discovers and develops therapeutic compounds to fight
infection, inflammation and cancer. The company bridges the gap
between academic discoveries and pharmaceutical commercialization
and focuses on conditions that have significant unmet medical
needs in medium sized markets.
# # #